Applications will open in October
Sponsor: SNMMI Mars Shot Fund and the Lobular Breast Cancer Alliance (LBCA)
Invasive lobular carcinoma (ILC), also known as lobular breast cancer, is the sixth most frequently diagnosed cancer of women in the US with nearly 44,000 new patients diagnosed each year. Research indicates that ILC is a unique histological subtype of breast cancer with distinct biological and behavioral differences. It’s time to advance research to better understand ILC and its differences and refine treatments for patients with lobular breast disease.
Selection Criteria/Review Process
The SNMMI Committee on Awards Chair will appoint SNMMI members with expertise in the subject matters of the proposed research to assess and evaluate the applications, along with the LBCA Scientific Committee and two (2) ILC patient advocates.
Research projects that focus on ILC studies and that include radionuclide imaging or therapy are of a particular interest and will be favored during the review process. Priority projects may have radionuclide imaging as the primary focus of the proposed research, or alternatively, research may investigate methods that integrate other imaging and/or molecular science with radionuclide methods, including research focusing on hybrid imaging techniques such as PET/CT, SPECT/CT and PET/MRI.
In assessing the applications evaluators will consider the following questions:
SNMMI grant proposals are reviewed in confidence; reviewers agree to not share the proposals that they are assigned to review, unless requested by the SNMMI Committee on Awards; furthermore, SNMMI is not authorized to release the identities of the proposal reviewers to the applicants.
Grant Report Requirements
All posters, publications and oral presentations must contain appropriate acknowledgement of this grant support by identify SNMMI and the LBCA